Trends in Prices of Drugs Used to Treat Metastatic Non–Small Cell Lung Cancer in the US From 2015 to 2020

Desai, Aakash; Scheckel, Caleb; Jensen, Chelsee; Orme, Jacob J.; Williams, Colt; Shah, Nilay D.; Leventakos, Konstantinos; Adjei, Alex A.

doi:10.1001/jamanetworkopen.2021.44923

Cited by 22 publications

(15 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cancer drugs are very expensive in the United States (see Table 1 for drug prices). Even though there are multiple drugs in each class targeting an oncogene product, in-class competition does not appear to put a downward pressure on prices as happens in other areas of the economy, and prices continue to remain high [ 135 , 136 ]. Since global pricing follows the United States pricing, targeted drugs for oncogene-addicted NSCLC remain high globally and, in most countries, these agents are unaffordable to the majority of the NSCLC population [ 136 , 137 ].…”

Section: Cost and Accessmentioning

confidence: 99%

Challenges in the Use of Targeted Therapies in Non–Small Cell Lung Cancer

2022

Self Cite

View full text Add to dashboard Cite

Precision oncology has fundamentally changed how we diagnose and treat cancer. In recent years, there has been a significant change in the management of patients with oncogeneaddicted advanced-stage NSCLC. Increasing amounts of identifiable oncogene drivers have led to the development of molecularly targeted drugs. Undoubtedly, the future of thoracic oncology is shifting toward increased molecular testing and the use of targeted therapies. For the most part, these novel drugs have proven to be safe and effective. As with all great innovations, targeted therapies pose unique challenges. Drug toxicities, resistance, access, and costs are some of the expected obstacles that will need to be addressed. This review highlights some of the major challenges in the use of targeted therapies in NSCLC and provides guidance for the future strategies.

show abstract

Section: Cost and Accessmentioning

confidence: 99%

Challenges in the Use of Targeted Therapies in Non–Small Cell Lung Cancer

2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…It is possible that immunotherapy for early-stage NSCLC may follow the pattern established in advanced NSCLC, where survival has been significantly improved for most patients. However, the benefits in the early-stage setting must be weighed against the adverse effects and risks of adding immunotherapy, including the substantial financial toxicity with these expensive therapies . The optimal timing, duration, and sequence of immunotherapy with other systemic therapies are only now beginning to be defined.…”

Section: Discussionmentioning

confidence: 99%

“…However, the benefits in the early-stage setting must be weighed against the adverse effects and risks of adding immunotherapy, including the substantial financial toxicity with these expensive therapies. 53 The optimal timing, duration, and sequence of immunotherapy with other systemic therapies are only now beginning to be defined.…”

Section: The Neoadjuvant Vs Adjuvant Immunotherapy Debatementioning

confidence: 99%

Perioperative Immune Checkpoint Inhibition in Early-Stage Non–Small Cell Lung Cancer

et al. 2023

View full text Add to dashboard Cite

ImportanceAlthough cancer-related mortality continues to decline, lung cancer remains the No. 1 cause of cancer deaths in the US. Almost half of the patients with non–small cell lung cancer (NSCLC) are diagnosed with early-stage, local or regional disease and are at high risk of recurrence within 5 years of diagnosis.ObservationsImmune checkpoint inhibitors (ICIs) have improved outcomes for patients with metastatic NSCLC and have recently been tested in multiple clinical trials to determine their efficacy in the neoadjuvant or adjuvant setting for patients with local or regional disease. The landscape for perioperative ICIs in lung cancer is evolving rapidly, with recently reported and soon to mature clinical trials; however, the recent data highlight the potential of ICIs to increase response rates and decrease rates of relapse in early stages of lung cancer. Concurrently, novel applications of cell-free DNA may guide perioperative management strategies.Conclusions and RelevanceThis article reviews the various approaches of incorporating perioperative use of immunotherapeutic agents for the treatment of early stages of NSCLC.

show abstract

“…Matching available therapies to older patients will be the main challenge for the next decades. In fact, anticancer therapies are becoming extremely expensive [17] and the risk of poor efficacy due to the erroneous assessment of eligibility should be avoided. Evaluation of molecular vulnerabilities of cancer cells should be integrated with reliable clinical assessment of the patient.…”

Section: Moving Forward and Beyond Body Composition Changes: Accelera...mentioning

confidence: 99%

Sarcopenia, biological age and treatment eligibility in patients with cancer

Laviano¹

2022

Current Opinion in Clinical Nutrition &Amp; Metabolic Care

View full text Add to dashboard Cite

Purpose of reviewCancer incidence will dramatically increase, especially among older adults, during the next few decades. This may lead to bankruptcy of the healthcare systems worldwide if the current approach to treatment eligibility is not improved. In fact, current treatment personalization is mostly focusing on the genetic and molecular characteristics of cancer cells, whereas clinical characterization of patients is still dependent on gross variables (i.e. chronological age, BMI, comorbidities, Performance Status and so on). This could have contributed to the poor performance of many anticancer drugs in the real-world setting when compared with the results obtained in prospective, randomized clinical trials. Recent findingsThe role of chronological age in identifying patients with increased likelihood to respond to therapies has been challenged, pointing to biological age (i.e. accumulated damage to biological systems over the life course, leading to loss of reserve and capacity to respond to challenges) as a robust predictor of outcome encompassing genetic, phenotypic and clinical factors. Sarcopenia has been proposed as a reliable clinical index of biological age, but the complexity of body composition changes occurring during tumour growth appears to preclude its routine use when assessing eligibility in cancer patients.

show abstract

Trends in Prices of Drugs Used to Treat Metastatic Non–Small Cell Lung Cancer in the US From 2015 to 2020

Abstract: This cross-sectional study examines trends in costs of brand-name medications for treatment of non–small cell lung cancer and within-class price differences between these medications in the US from 2015 to 2020.

Cited by 22 publications

References 9 publications

Challenges in the Use of Targeted Therapies in Non–Small Cell Lung Cancer

Challenges in the Use of Targeted Therapies in Non–Small Cell Lung Cancer

Perioperative Immune Checkpoint Inhibition in Early-Stage Non–Small Cell Lung Cancer

Sarcopenia, biological age and treatment eligibility in patients with cancer

Contact Info

Product

Resources

About